What is an FDA complete response letter (CRL)?
What a complete response letter is
A complete response letter, or CRL, is the letter the US Food and Drug Administration sends a company when it has finished reviewing a drug or biologic application and will not approve it as submitted. The regulation puts it this way: the FDA sends a complete response letter if the agency determines that we will not approve the application or abbreviated application in its present form
.
The words in its present form
carry the meaning. A CRL closes one review cycle without approval. It does not bar the product from being approved later, and the letter itself is written to tell the company what would need to change.
A CRL is one of the two outcomes the FDA can deliver by a PDUFA date. The other is approval.
What the letter says
Under the FDA’s regulations a complete response letter:
- describes all of the specific deficiencies the agency identified in the application;
- reflects the FDA’s complete review of the data submitted, and identifies any amendments it has not yet reviewed;
- recommends, when possible, actions the applicant might take to put the application in condition for approval.
There is one exception to the complete list. If the FDA decides the submitted data are inadequate to support approval, it may issue the letter without first carrying out required inspections or reviewing the proposed labeling. A later cycle can therefore raise points the first letter did not.
Common reasons for a CRL
The FDA summarizes them in one sentence: it issues CRLs for various reasons, most related to safety and efficacy concerns, manufacturing deficiencies, and bioequivalence issues
.
- Safety and efficacy: the clinical evidence does not, in the FDA’s view, show that the product works or that its benefits outweigh its risks.
- Manufacturing: problems with how or where the product is made.
- Bioequivalence: the application has not shown that the product performs like the existing product it is compared with.
The category matters because it shapes what comes next. A labeling or manufacturing point can sometimes be answered with documents. A request for more clinical evidence can mean a new trial. Only the letter says which, which is the reason to read it rather than a summary of it.
What the company can do next
For drug applications, the regulation gives the applicant three options after a complete response letter:
- Resubmit the application, addressing all the deficiencies identified in the letter.
- Withdraw the application. A withdrawal is
without prejudice to a subsequent submission
, so the company can file again later. - Ask the FDA for an opportunity for a hearing on whether there are grounds for denying approval.
The regulation for biologics lists the first two: resubmit or withdraw.
There is a time limit of sorts. If the applicant takes none of these actions within one year of the letter, the FDA may treat that as a request to withdraw the application, unless the applicant has asked for an extension. The regulation says the FDA will grant any reasonable request for one.
Resubmission classes and timelines
When a company resubmits, the FDA classifies the resubmission, and the class sets the length of the new review.
| Class | What it contains | New review period |
|---|---|---|
| Class 1 | Only limited items, such as final or draft labeling, safety updates, stability updates, commitments to run post-approval studies, assay validation data, or a minor reanalysis of data already submitted | 2 months from receipt |
| Class 2 | Anything else, including any item that would need to go before an advisory committee | 6 months from receipt |
These periods come from the same commitment letter that sets PDUFA review goals, and they work the same way: the FDA aims to act on 90 percent of resubmissions within them. A resubmission therefore produces a new goal date, and the review can again end in approval or in another complete response letter.
The review period starts when the FDA receives the resubmission. The time the company takes to prepare it, which can include running a new study, is not part of the 2 or 6 months.
How CRLs become public
For most of the letter’s history, the public learned about a CRL from the company that received it, through a press release or a filing with the Securities and Exchange Commission, if the company announced it at all. The FDA did not publish the letters for applications that were still pending, and a company’s account could be selective. The FDA cites a 2015 analysis by its own researchers that found sponsors left out 85 percent of the agency’s safety and efficacy concerns when announcing that an application was not approved.
That changed in 2025:
- On 10 July 2025 the FDA published more than 200 complete response letters, issued for applications submitted between 2020 and 2024 that were approved afterwards.
- On 4 September 2025 it announced that it would release future CRLs promptly after issuing them to sponsors, and published 89 more letters, issued from 2024 onward, for applications that were pending or withdrawn.
The letters are available through openFDA as a searchable table and as a dataset. They are redacted for trade secrets and confidential commercial information, so parts of a letter can be blacked out. When we checked on 6 October 2026 the dataset held 458 letters and was last updated on 13 August 2026.
Company disclosure still matters. A press release or SEC filing can reach the public before the FDA’s copy of the letter is posted.
Complete response letters in TrialRedline
The FDA calendar has a complete response letter event type. Each entry gives the letter date, the drug and company, and a link to the letter’s record in the openFDA dataset. Show complete response letters in the calendar.
We list a letter only when the company named in it matches a company we track and the letter’s opening paragraph names one of that company’s drugs. Letters we cannot match that precisely stay unpublished, so the calendar shows fewer CRLs than the FDA’s full dataset.
A drug’s page shows its FDA events together, so a complete response letter appears next to any announced PDUFA dates and approval decisions for the same drug, and next to the clinical trials studying it.
Common questions
What does CRL stand for at the FDA?
CRL stands for complete response letter. It is the letter the FDA sends when it has finished reviewing a drug or biologic application and decided it will not approve the application in its present form.
Is a complete response letter a rejection?
It means the application was not approved in this review cycle. It is not necessarily the end of the application: the company can fix the deficiencies the letter lists and resubmit, and a withdrawal does not prevent a later submission.
How long does the FDA take to review a resubmission after a CRL?
The FDA classifies each resubmission. A Class 1 resubmission, limited to items such as labeling, safety updates or minor reanalyses, starts a 2-month review. A Class 2 resubmission, which covers everything else, starts a 6-month review.
How long does a company have to respond to a CRL?
For drug applications, the FDA may treat a failure to resubmit, withdraw or request a hearing within one year of the letter as a request to withdraw the application, unless the company has asked for more time. The regulation says the FDA will grant any reasonable request for an extension.
Are FDA complete response letters public?
Many now are. In July 2025 the FDA published more than 200 CRLs for applications that were later approved, and in September 2025 it said it would release future CRLs promptly after issuing them. The letters are in an openFDA dataset, with trade secrets and confidential commercial information redacted.
Does a CRL come on the PDUFA date?
It can. A complete response letter is one of the two ways the FDA can act on an application by its PDUFA goal date; the other is approval. The letter can also arrive before the goal date.
Sources
Every statement on this page was checked against these primary sources on 6 October 2026. Rules and programs change, so read the source before relying on a detail.
- 21 CFR 314.110: complete response letter to the applicant (drugs)
- 21 CFR 601.3: complete response letter to the applicant (biologics)
- FDA: PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (PDF)
- FDA press announcement, 10 July 2025: publishing complete response letters
- FDA press announcement, 4 September 2025: real-time release of complete response letters
- openFDA: complete response letters dataset